GlobeNewswire

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
04/11/2026
The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting [...]
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
04/11/2026
New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a [...]
New Study Finds Nearly Half of Women Seeking Help for Menstrual Symptoms Say Their Concerns Were Dismissed
04/11/2026
Global Clue study of almost 12,000 people reveals widespread menstrual health challenges, with one in three who sought medical care told their symptoms were normal or not a problem. BERLIN, Nov. 04, 2026 (GLOBE NEWSWIRE [...]
TOMI Environmental Solutions, Inc. Announces Recurring Consumable Agreement with Global Eye Health Company
04/11/2026
Combined revenue from two facilities is approximately $750,000 FREDERICK, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company Developing Radiology Models
04/11/2026
Repeat order underscores demand for full-fidelity data at the scale required to train foundation AI models in radiology MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” [...]
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
04/11/2026
DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure [...]
Neuronetics Reports Third Quarter 2026 Financial and Operating Results
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient [...]
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
04/11/2026
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending [...]
MediPharm Labs Appoints Greg Hunter as Chief Executive Officer and Director
04/11/2026
Appointment reflects the Board’s confidence in Mr. Hunter’s proven leadership and strengthens MediPharm’s focus on profitable growth, operational excellence and long-term value creation TORONTO, Nov. 04, 2026 (GLOBE [...]
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
04/11/2026
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will [...]
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
04/11/2026
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
04/11/2026
Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular [...]
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
04/11/2026
– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide – – [...]
Medline Reports Third Quarter and Nine Months 2026 Results
04/11/2026
Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.8% Nine months net sales of $ [...]
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
04/11/2026
- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + [...]
Kane Announces Publication of Real-World Evidence in the International Wound Journal
04/11/2026
Study reports improvements across multiple wound-healing outcomes associated with adjunctive use of revyve® Antimicrobial Wound Gel WINNIPEG, Manitoba, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ( [...]
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
04/11/2026
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S. [...]
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
04/11/2026
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract [...]
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
04/11/2026
Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum